Featured Projects

Non-Specific Respiratory Symptoms (NSRS) Study

Publication:

David B Price, Roland Buhl, Adrian Chan, Daryl Freeman, Elizabeth Gardener, Clifford Godley, Kevin Gruffydd-Jones, Lorcan McGarvey, Ken Ohta, Dermot Ryan, Jörgen Syk, Ngiap Chuan Tan, TzeLee Tan, Mike Thomas, Sen Yang, Priyanka Raju Konduru, Marcus Ngantcha, Martina Stagno d’Alcontres, Therese S Lapperre. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med 2017.

[PubMed] [Full Text]

Abstract:

David Price, Roland Buhl, Anne Copland, Daryl Freeman, Clifford Godley, Kevin Gruffydd-Jones, Therese Lapperre, Lisa Law, Lorcan Mcgarvey, Ken Ohta, Dermot Ryan, Jorgen Syk, Ngiap Chuan Tan, Tze Lee Tan, Mike Thomas, Adrian Chan. Predictive value of FeNO in patients with non-specific respiratory symptoms: a randomised controlled trial. Eur Respir J 2017; 50: PA3886.

[Full Text]

FFLUX Study

Publication:

Omar S. Usmani, Anu Kemppinen, Elizabeth Gardener, Vicky Thomas, Priyanka Raju Konduru, Christina Callan, Andrew McLoughlin, Vanessa Woodhead, Adam Brady, Elizabeth F Juniper, Peter J Barnes, David B. Price. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. J Allergy Clin Immunol Pract 2017; 5(5): 1378-1387.e5.

[PubMed] [Full Text]

CRITIKAL Study

Publication:

David B. Price, Miguel Román-Rodríguez, R. Brett McQueen, Sinthia Bosnic-Anticevich, Victoria Carter, Kevin Gruffydd-Jones, John Haughney, Svein Henrichsen, Catherine Hutton, Antonio Infantino, Federico Lavorini, Lisa M. Law, Karin Lisspers, Alberto Papi, Dermot Ryan, Björn Ställberg, Thys van der Molen, Henry Chrystyn. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract 2017; 5(4): 1071-81.e9.

[PubMed] [Full Text]

ELIOT Study

Publication:

Sinthia Bosnic-Anticevich, Christina Callan, Henry Chrystyn, Federico Lavorini, Vasilis Nikolaou, Vicky Kritikos, PN Richard Dekhuijzen, Nicolas Roche, Leif Bjermer, Cynthia Rand, Nicholas Zwar, David B Price. Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. J Asthma 2018: 55(1): 79-88.

[PubMed] [Full Text]

Abstract:

H Chrystyn, R Dekhuijzen, C Rand, S Bosnic-Anticevich, N Roche, F Lavorini, V Thomas, J Steele, P Raju, D Freeman, I Small, J Canvin, D Price. Evaluation of inhaler technique mastery for budesonide formoterol Spiromax® compared with Symbicort Turbohaler® in adult patients with asthma: primary results from the Easy Low Instruction Over Time [ELIOT] Study. Thorax 2015; 70(S3): A154-A155.

[Full Text]

HI-TEC Study

Publication:

Henry Chrystyn, David B. Price, Mathieu Molimard, John Haughney, Sinthia Bosnic-Anticevich, Federico Lavorini, John Efthimiou, Dawn Shan, Erika Sims, Anne Burden, Catherine Hutton, Nicolas Roche. Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study. BMC Pulm Med 2016; 16(1):12.

[PubMed] [Full Text]

EOSINOPHILS in Asthma Study

Publication:

David B Price, Anna Rigazio, Jonathan D Campbell, Eugene R Bleecker, Christopher J Corrigan, Mike Thomas, Sally E Wenzel, Andrew M Wilson, Mary Buatti Small, Gokul Gopalan, Valerie L Ashton, Anne Burden, Elizabeth V Hillyer, Marjan Kerkhof, Ian D Pavord. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3(11): 849–58.

[PubMed] [Full Text]

ELEVATE Study

OPRI conducted two separate, 2-year pragmatic trials designed to evaluate the effectiveness of leukotriene-receptor antagonist (LTRA) for primary care patients receiving asthma therapy under real-world conditions. The study compared LTRA with either an inhaled glucocorticoid for first-line asthma-controller therapy or a long-acting beta2-agonist (LABA) as add-on therapy in patients already receiving inhaled glucocorticoid therapy, and recruited over 300 patients from 53 primary care practices in the United Kingdom.

The study found that at 2 months, LTRA was equivalent to an inhaled glucocorticoid as first-line controller therapy and to LABA as add-on therapy for diverse primary care patients.

This work has now been published in The New England Journal of Medicine.

Publication:

David Price, Stanley D. Musgrave, Lee Shepstone, Elizabeth V. Hillyer, Erika J. Sims, Richard F.T. Gilbert, Elizabeth F. Juniper, Jon G. Ayres, Linda Kemp, Annie Blyth, Edward C.F. Wilson, Stephanie Wolfe, Daryl Freeman, H. Miranda Mugford, Jamie Murdoch, Ian Harvey. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364(18): 1695-707.

[PubMed] [Full Text]